INSUBCONTINENT EXCLUSIVE:
4 min read Last Updated : Jul 25 2024 | 11:15 PM IST
India may have a dengue vaccine by 2026, said a top executive of vaccine
mosquito-borne disease that claimed 485 lives last year.
Dengue has become a major public health concern in India with 289,235 cases
According to data from the National Center for Vector Borne Diseases Control, there were 19,447 cases of dengue which resulted in 19 deaths
apply for approvals for the phase 2 clinical trials soon
trials are done on a small group of people to determine the safety of the vaccine, while phase 2 and phase 3 trials are conducted to test a
The company aims to start phase 2 and phase 3 trials soon.
Japanese pharmaceutical company Takeda has also initiated local clinical
A Takeda India spokesperson told Business Standard they had received the no-objection certification (NoC) for clinical trials from Indian
as per the local regulation in India and are committed to completing the trial at the earliest, followed by submission to Indian health
getting approval from Indian regulatory authorities
As soon as we get clearance, we will launch the vaccine
said.
Takeda has developed Qdenga, a tetravalent vaccine for dengue
It is already available for children and adults in the private market in Europe, Indonesia and Thailand, and in private, in some public
programmes in Argentina and Brazil
Takeda follows a dual pricing strategy in both private and public markets, and as such prices in the private market are higher in Europe
long-term partnership with IDT Biologika GmbH.
The doses made by BE will ultimately be made available for procurement by the governments
in endemic countries by 2030 at the latest to support National Immunization Programmes.
Qdenga is a tetravalent, live, attenuated, dengue
vaccine in multi-dose vials
BE would produce a multi-dose vial for this vaccine, something they currently do not have
It added that multi-dose vials offer economic and logistical advantages for National Immunisation Programmes by minimising packaging and
storage expenses, while also reducing medical and environmental waste.
Gary Dubin, President, Global Vaccine Business Unit, Takeda told
Business Standard in February that the global clinical development of this vaccine had covered over 28,000 individuals across dengue endemic
and non-endemic countries, and shown an efficacy of around 84 per cent against hospitalised dengue
This was irrespective of whether the individual was exposed to dengue previously or not
Besides Takeda and IIL, the Serum Institute of India and Panacea Biotec are working to develop a dengue vaccine.First Published: Jul 25 2024
